The naphtosultam derivative RP 62203 (fananserin) has high affinity for the dopamine D4 receptor

European Journal of Pharmacology
E HeuilletJ C Blanchard

Abstract

The dopamine D4 receptor is a potential target for novel antipsychotic drugs. Most available compounds with affinity for the dopamine D4 receptor also bind to dopamine D2 receptors. This report describe the affinity of the 5-HT2A receptor antagonist RP 62203 (fananserin) for the human dopamine D4 receptor. Fananserin displaces [3H]spiperone binding to recombinant human dopamine D4 receptors with a Ki of 2.93 nM. This compares with an affinity (Ki) of 0.37 nM for the rat 5-HT2A receptor and of 726 mM for the rat dopamine D2 receptor. [3H]Fananserin can be used to label the recombinant dopamine D4 receptor expressed in Chinese hamster ovary cells with a KD of 0.725 nM. Fananserin is, thus, the first compound to be reported that distinguishes between dopamine D4 and D2 receptors.

References

Jul 9, 1992·Nature·H H Van TolV Jovanovic
Oct 1, 1985·Analytical Biochemistry·P K SmithD C Klenk
Feb 1, 1995·Journal of Clinical Psychopharmacology·R L Borison
Jul 1, 1994·Trends in Pharmacological Sciences·P Seeman, H H Van Tol

❮ Previous
Next ❯

Citations

May 7, 1998·European Journal of Pharmacology·H O KalkmanM D Tricklebank
Dec 2, 1998·Neuropharmacology·J F López-GiménezG Mengod
Jul 1, 1997·Expert Opinion on Investigational Drugs·G P Reynolds
Jun 30, 2000·Japanese Journal of Pharmacology·D M Helmeste, S W Tang
Jan 11, 2002·Journal of Medicinal Chemistry·Stephen R FletcherAngus M MacLeod
Feb 15, 2001·Journal of Medicinal Chemistry·M RowleyP H Hutson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here